Index

A
Abecma® (idecabtagene vicleucel) 65, 130
acceptable quality limit (AQL) 80
Access Consortium 125, 185
accreditation 146
Act on the Safety of Regenerative Medicine (ASRM) 5, 6, 144–145, 146, 159
adenoviruses 51
adopter cell therapies
Albinon, Ramon 95
Alliance for Regenerative Medicine (ARM) 62, 77
allergic cell therapies
definition 215
logistics of 86, 91, 93
manufacturing site concept 93
shelf-life 92, 93
storage facilities 92, 94
supply chain 93
Altenburger, Ralf 205

Adenosine deaminase deficiency (ADA) 11
Advanced Regenerative Medicine Institute (ARMI) 76
advanced therapy investigational medicinal products (ATIMPs) 86
advanced therapy medicinal products (ATMPs) 207
classification of 4, 121, 122
criteria for 121
definition 215
EU GMP guidance 88

adverse drug reactions (ADRs) 199
adverse events
delayed 53, 114
reporting 155, 197, 198, 199
risk assessment 114
serious adverse events (SAEs) 197, 198, 219
unexpected serious adverse drug reactions (USADRs) 199

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 123
Alipogene tiparvovec 94

EU legislation 117–118
factors that will be important for success 207
hospital exemption 122
labeling requirements 61, 88
MAA process and timeline 119, 120
regulation of 4
starting materials 123
storage and distribution 86
traceability considerations 58

Advanced Regenerative Medicine Institute (ARMI) 76
advanced therapy investigational medicinal products (ATIMPs) 86
advanced therapy medicinal products (ATMPs) 207
classification of 4, 121, 122
criteria for 121
definition 215
EU GMP guidance 88

Altenburger, Ralf 205
American Society for Testing and Materials (ASTM) 76, 77
American Society of Gene and Cell Therapy (ASGCT) 13
Anderson, Steven A. 103
animal models 39, 52
annual reports 173
Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products (FDA) 10
Asilomar Conference on Recombinant DNA 9
assays 25
Association for the Advancement of Blood and Biotherapies (AABB) 59
Australia 150, 188
biosecurity requirements 186
clinical trials 178
Gene Technology Regulations 183
Gene Technology Regulator 183, 185
Health Technology Assessment (HTA) 186
Intergovernmental Gene Technology Agreement 183
legislation 177
Medical Services Advisory Committee (MSAC) 186
medicare benefits schedule (MBS) 186
Office of the Gene Technology Regulator (OGTR) 177, 178, 185, 186
Pharmaceutical Benefits Advisory Committee (PBAC) 186
pharmaceutical benefits scheme (PBS) 186
prescription medicines regulation 181–186
regenerative medicines sector 177
regulatory framework for biologicals 179
standards for biologicals 181
Therapeutic Goods Administration (TGA) 177, 178, 179
Australian Biotechnologies Pty Ltd. 180
Australian Guidelines for Prescription Medicines (ARGPM) 183
Australian Register of Therapeutic Goods (ARTG) 178
biological products listed on 180
biological products listed on 182
cellular therapies listed on 182
gene therapy prescription medicines listed on 186
autologous cell therapy
approved products 72
challenges 73
definition 215
logistics of 86, 90, 91, 92
manufacturing controls 72
manufacturing site concept 91, 92
shelf-life 91, 92
supply chain 90
autologous transplantation 11
automated systems 76, 77
automation 75
Avery, Oswald 3
AveXis 17
axicabtagene ciloleucel (Yescarta®) 65, 130, 182
case study 174
marketing authorization approval 164

B
Bacillus Calmette-Guerin vaccine 72
batch release 80
Bauer, Steven 105
BBM-H901 injection 164
benefit-risk paradigms 42
Berg, Paul 9
bioactivity 68
Biogen 130
biological drugs
cell therapies regulated as 133
gene therapies regulated as 134
biological products
Australian Register of Therapeutic Goods (ARTG) 180
Australian regulation of 179, 183
Class 3 180
Class 4 178, 180
classes in Australia 180
definition 133, 179, 215
HCT/Ps regulated as 35
labelling requirements 181
MOA 30
risk-based classification of 179
standards in Australia 181
TGA review pathways 178, 179
biologics license applications (BLAs) 51
biologics manufacturing facilities 77, 81
biopharmaceutical products
combination products 29–36
types classified as regenerative medicine 1
biosafety 143
biosecurity 186
blood and blood products 57
Blood Directive 2002/98/EC (EUBD) 57, 58, 119
breakthrough therapy drug procedures 172
brexucabtagene autoleucel (Tecartus™) 65, 130, 182
Breyanzi® (lisocabtagene maraleucel) 65
Brubaker, Scott 104
Bryan, Wilson 102, 103, 104
Bush, George HW 14
Bush, George W. 7, 8, 15
Byrnes, Andrew 105

C
Califano, Joseph 9
California 15
California Institute for Regenerative Medicine 16
Canada
 approved CGT products 129, 130
key regulatory provisions for CGT Products 131
other regulatory pathways and programs 138
regulatory framework 129–130, 132
regulatory pathways for CGT products 131–134
Canadian Standards Association (CSA) 135
cancer vaccines 72
Canniere, Megan Zoschg 205, 206
Cartagena Act 148, 215
Cartagena Protocol 143
Carticel 11, 72
cartilage, frozen, irradiated 180
CBER Advanced Technologies Team (CATT) 40
Celgene 130
cell and gene therapies (CGTs)
 accelerated MAA procedures 172
 approved products 72, 129
 autologous therapies 72
 challenges 175
 CMC readiness 72, 78
 common features 24
 critical process parameters (CPPs) 74
 critical quality attributes (CQAs) 73
 CTA procedures in China 170
current trends 49
diverse characteristics of products 72
early phase trials 110
example products 100
first clinical trial in China 163
general features 23
immunogenicity 26
later stage studies 111
long-term follow-up 26
Lot Release Program 138
MAA procedures in China 171
manufacturing 25
manufacturing controls 71–80
market access 174
marketing authorization 138
notice of compliance with conditions (NOC/c) 138
“off-the-shelf” products 72
potency tests 55
preclinical assessment 51
priority review 139
product types 73
regulation in China 163–175
regulation in NZ 188
regulatory considerations 51–54
regulatory environment in Singapore 191–200
regulatory guidance documents 135
regulatory pathways in Canada 131–134
safety in clinical trials 25
suggested points to consider 82
technologies 23
cell banks
definition 215
master cell banks (MCBs) 218
product-specific challenges 73
working cell banks (WCBS) 220
cell-based advanced therapies
comparability studies 62
critical process parameters (CPP) 62
critical quality attributes (CQA) 62
cryopreservation of 64
delivery systems 68
final products 63–68
human cell or tissue-based starting materials 57–62
regulation of 4
release testing 65, 66
samples for testing, stability, and retention 66
special considerations 57–69
Drug Registration Regulation (DRR) 171
first clinical trial for CGT products 163
gene therapy developments 163
health authorities 165
investigational new drug (IND) applications 164
license renewal 173
local provincial and municipal Medical Products Administrations (MPAs) 165
MAA procedures 171, 172
market access 174
National Health Commission (NHC) 163
National Medical Products Administration (NMPA) 163
postapproval change management 173
regulatory authorities 164, 165
China Food and Drug Administration (CFDA) 164
ChondroCelect 4, 120
chondrocytes (Ortho-ACI) 180, 182
Clinical Trial Act (Japan) 153, 155
clinical trial applications (CTAs) 178
for cell therapy products 137
for CGT products 170
in China 170, 171
postauthorization changes and activities 137
pre-CTA meetings 136
requirements for 136
clinical trial authorizations (CTAs) 198
application process 198, 199
application requirements 199, 201
clinical trial certificates (CTCs) 198
clinical trial in-country representatives 155
clinical trial notifications (CTNs) 154, 198
application process 198, 199
application requirements 199, 201
clinical trials
conducted on ethical grounds 153
current trends 49
design and endpoint validation 43, 44
eyear phase 110
EU regulation 119
EU requirements 124
expanded access (or compassionate use) 153
first human trials 11, 16
Health Canada requirements 136–137
human stem cell guideline 143
Japanese guidelines 153
later stage studies 111
operations in Japan 155
Phase 1 trials 49
Phase 2 trials 49
Phase 3 trials 49
phased trials 154
pivotal studies 42–43
preclinical studies 51
preparing for first-in-human studies 39
regulation in Singapore 198, 200
safety of CGTs in 25
US requirements 110
ClinicalTrials.gov 12, 13, 14
clinical trials notification (CTN) 178
Clinton, Bill 6, 14, 15
cloning
current state laws 7
evolution of 5–6
“Cloning Human Beings” (President’s Council) 8
clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR-Cas9 24, 73, 207
CRISPR-Cas proteins 204
definition 216
studies with embryos 163
CMC readiness
definition 72
key questions to consider 78
prior to Phase III or licensing trials 78
Code of Federal Regulations (US)
21 CFR 600–680 6
21 CFR 1270 4, 14, 15
21 CFR 1271 6, 15, 16, 17, 99
Collins, Francis 13
combination products 29–36
cell therapies regulated as 134
constituent parts 29
cross-packaged 30
cross-labeled 30
definition 216
elements 30, 31
good manufacturing practices (GMPs) 36
good tissue practices (GTPs) 36
primary mode of action (PMOA) 30
regulatory definition 29
request for designation (RFD) 32–33
single entity 30
types 73
types of 31
combined ATMPs (cATMPs)
  classification 122
  classification of 4
  definition 216
  legal definition 121
commercial-scale manufacturing 79–80
Committee for Advanced Therapies (CAT) 6, 118, 119, 216
Committee for Human Medicinal Products (CHMP) 6, 119
common technical document (CTD)
  electronic (eCTD) 155
  Module 1 106
  Module 2 107
  Module 3 107
  structure 106
Commonwealth Gene Technology Act (Australia) 183
comparability 75
comparability studies
  considerations for 62
critical elements 75
definition of 75
design considerations 62
Comparable Overseas Regulators (COR) 184
complaints 109
conditional approvals
  Japanese conditional expedited approval system 147, 148
  procedures in China 172
constituent parts 29, 30–31
consultation meetings
  with China CDE 170
  with Japan PMDA 152
  regulatory science (RS) strategy consultations 152
consultation, product 192
contained use 124
continuous manufacturing 76
contract development manufacturing organizations (CDMOs) 79
Co-ordination group for Mutual Recognition and decentralized procedures – human (CMDh) 117
council for international organizations of medical sciences (CIOMS) 197
Covid-19 pandemic 17, 207
Covid-19 vaccines 122
critical process parameters (CPPs) 62, 73, 74, 75
critical quality attributes (CQAs) 62, 73, 74, 75, 216
cryopreservation
  of cell-based advance therapies 64
definition 216
excipients 64, 65
labeling requirements 67
and logistics 91
cryoprotectants 64
cryostorage facilities 92
culture-based mycoplasma testing 66
culture-based sterility testing 66
Cures 2.0 114
current good manufacturing practices (CGMPs)
  facility strategies 78
  for combination products 35
current good tissue practices (CGTPs)
  for combination products 35
  for HCT/Ps 35, 36
Current Guidelines on the Regulation of Therapeutic Products in New Zealand 187
current trends 49–55

dangerous goods classification 93
databases 13
dealer’s license 200
dealings involving intentional release (DIR) licenses 185
dealings not involving intentional release (DNIR) licenses 185
delayed adverse events 53, 114
deliberate release 124
delivery systems 68
development safety update reports (DSURs) 170
device MOA 31
devices 133
Dickey-Wicker Amendment 6, 14
dimethyl sulfoxide (DMSO) 64
Directive 2006/17/EC 87
Directive 2009/41/EC 119, 124
Directive 2009/120/EC 4, 5, 6
DiSilva, Ashanti 11
distribution 85–96
  of advanced therapy investigational medicinal products 86
  of advanced therapy medicinal products 88
Regulation of Regenerative Medicines: A Global Perspective

EU tissues and cells directives 87
of frozen regenerative medicines 94
Division of Cellular and Gene Therapies (DCGT) 102
definition 216
organizational structure 105
DNA 3
DNA editing 24
documentation. See common technical document (CTD)
Dolly the Sheep 5–6
donor eligibility
commercial manufacturing strategy 80
product-specific challenges 73
requirements 58
US regulations 108
donors 216
donor testing
Australian requirements 181
US requirements 108, 109
Drug-Device Combination Products 134
drug lists 174
Drug/Medical Device Combination Products
Policy 134
drug mode of action 31
Drug Registration Regulation (DRR) 171
drugs
biological 133, 134
product definition 133

E
Eacho, Melanie 105
electronic common technical document (eCTD) 155
embryonic stem cells (ESCs)
current state laws 7
EU regulations 125
human (hESCs) 6, 217
NIH guidelines 15
end-of-phase 1 (EOP1) meetings 104
end-of-phase 2 (EOP2) meetings 104
gineered stem cells 216
environmental assessments 112
environmental impact statement (EIS) 112
Environmental Protection Authority (EPA) 188
Environment Canada 134
equipment 80
Ethics Committee (EC) approvals 171
ethnic factors 153
EudraGMP 198
European Agency for the Evaluation of Medicinal Products (EMEA) 4
European Blood Directive (EUBD) 123
European Commission (EC) 4, 6
European Directive for Tissues and Cells (EUTCD) 123
European Economic Area (EEA) states 117
European Heads of Medicines Agencies 117
European Medicines Agency (EMA) 4, 117
Cell Products Working Party 117
Cell Therapies Working Party 119
CMC requirements 55
definition of somatic cell therapy 23
Gene Therapy Working Party 117, 119
PRIME scheme 218
European Medicines Directive 2001/18/EC 119, 124
European Tissue and Cells Directive 2004/23/EC (EUTCD) 57, 58, 87, 118
European Union (EU)
ATMP legislation 117–118
GMP for advanced therapy medicinal products 88
regenerative medicine history 4
regulation of regenerative medicine 6, 19
regulatory framework for regenerative medicines 117–126
tissues and cells directives 87
evidence generation 45
exosomes 73
expanded access (or compassionate use) 153
expedited review
Japanese conditional expedited approval system 147, 148
US pathways 45
ex vivo gene therapy 216

F
faecal microbiota, frozen 180
FDA Amendments Act of 2007 (FDAAA) 12
Federal Food, Drug and Cosmetic Act (FD&C Act) 6, 34
fetal tissue research 17
fibroblasts 72
finding of no significant impact (FONSI) 112
first-in-human (FIH) studies in Japan 154
preparing for 39
fixed dose combinations 29
Food and Drug Administration (FDA). See US Food and Drug Administration (FDA)
Food and Drug Administration Modernization Act of 1997 (FDAMA) 12
Food and Drug Regulations (FDR) 129, 131, 134
Food and Drugs Act (F&DA) 129
Fosun Kite 164, 174
Foundation for Accreditation of Cell Therapies (FACT) 59
French Anderson 11
fresh finished products 91
frozen regenerative medicines logistics 91
storage and distribution 94
funding 49, 50
future directions 203–207

G
Gavin, Denise 105
Gendicine 163, 174
gene marking 11, 12
Gene Technology Act (Australia) 177, 178, 183–185
Gene Technology Advisory Committee (GTAC) 187
Gene Technology Regulations (Australia) 183
Gene Technology Regulator (Australia) 183, 185
Gene Therapy Clinical Trial Monitoring Plan 15
gene therapy (GT) 10. See also cell and gene therapies (CGTs)
animal models 39
approved products 163, 164
Australian Register of Therapeutic Goods (ARTG) 186
benefit-risk paradigm 42
Cartagena Act for 148
CMC requirements 54
current trends 49, 50, 51–54
definition 23, 164, 216
developments in China 163
durability 45
early stage CMC considerations 40
enhanced review 11
evidence generation 45
example products 100
example products recently approved 135
first approved products 17
first FDA-approved AAV gene therapy 43
first human trials 11, 14
guidelines for clinical research 143
for hemophilia 54
immunogenicity, vector design, and optimization 40
limitations of understanding 41
logistics of 86, 92–94
long-term follow up (LTFU) 45, 46, 53
long-term safety 112–113
microbial vectors 55
non-viral vectors 50
off-target effects 26
patient preference 43–44
pivotal studies 42–43
preclinical assessment 52
preparing for first-in-human studies 39
products regulated as biological drugs 134
product types 73
for rare diseases 54
registered protocols 12
regulatory considerations 51–54
regulatory review 43–44
for retinal diseases 54
risk assessment 114
special considerations 39–47, 111
special expectations 109
supply chain 95
testing vectors 112
therapeutic dose selection 41
trial design and endpoint validation 43, 44
US regulations 107
vector heterogeneity 42
viral vectors 50
in vivo 218
gene therapy medicinal products (GTMPs)
classification of 4
definition 217
legal definition 121
logistics 92–93
genetically modified organisms (GMOs)
Australian biosecurity requirements 186
Australian regulation of 183
Regulation of Regenerative Medicines: A Global Perspective

H

Haseltine, William 3
Hazardous Substances and New Organisms (HSNO) Act (NZ) 188
Health Canada 130
Biologics and Radiopharmaceutical Drugs Directorate (BRDD) 130, 139
Centre for Biologics Evaluation (CBE) 130
Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics (CERB) 130
Centre for Regulatory Excellence, Statistics and Trials (CREST) 131
Drug/Medical Device Combination Products Policy 134
Food and Drug Regulations (FDR) 129, 131, 134
Health Products and Foods Branch (HPFB) 130
Lot Release Program 138
Medical Devices Regulations (MDR) 129, 131, 134
Office of Policy and International Collaboration (OPIC) 131
regulatory guidance documents 135
requirements for clinical trials 136–137
Safety of Cells, Tissues, and Organs for Transplantation Regulations (CTO Regulations) 129, 130, 131, 132
Special Access Program (SAP) 139
HealthNZ 187
Health Products Act (HPA) 191
Health Products (cell, tissue, and gene therapy products) Regulations 2021 191
Health Products (Clinical Trials) Regulations (Singapore) 198
Health Research Council of NZ 187
Health Sciences Authority (HSA) 191
guidance documents and checklists 193, 196
Innovation Office 192
Pharmaceutical Regulatory Information System (PRISM) 199
Health Technology Assessment (HTA) 186
hematopoietic progenitor cells (HPCs) definition 217
procurement sites 59
stability 60
hemophilia, gene therapy for 54
history of regenerative medicine 3–21
  country-specific overviews 4
  development timeline 14–17
HIV/AIDS 12
homologous use 131
hospital exemption 122, 217
Human Adult Stem Cells (Prochymal) 130
Human Biomedical Research Act (Singapore) 198
Human Cell and Tissue Establishment Registration (FDA) 59
human cells, tissues, or cellular or tissue-based products (HCT/Ps)
  approved products 72
  biological products 35
  cell or tissue procurement sites 58–59
  CGTP requirements 35, 36
  combination products 29–36, 37
definition 34, 217
donor eligibility requirements 58
donor screening requirements 181
labeling requirements 60
medical devices 36
on-site evaluation (OSE) 138
regulation of 4, 15
reportable deviations 109
Section 351 100
Section 361 99
starting materials 57–62
US regulations 99, 101
human embryonic stem cells (hESCs)
definition 6, 217
  Guideline for Human Embryonic Stem Cell Research (National Academies) 8
Human Genetic Resource Administration of China (HGRAC) 171
Human Research Ethics Committee (HREC) 178
human stem cell guidelines 143
human trials. See clinical trials
Hussey, Deirdre P. 103

idecabtagene vileucel (Abecma®) 65, 130
Imlygic (talimogene laherparepvec) 183
immunogenicity 25, 40, 217
individual case safety reports (ICSRs) 155
induced pluripotent stem cells (iPSCs)
  clinical trials with 143
definition 217
infectious disease testing 58
INInitial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) 40, 105
Innovation Office (Singapore) 192
Innovative Licensing and Access Pathway (ILAP) 125, 217
inspections 81
good clinical practice (GCP) 199
on-site evaluation (OSE) 138
Institute of Medicine (IOM) 13
Institutional Biosafety Committee Registration Management System (IBC-RMS) 13
institutional biosafety committees (IBCs) 12, 185
institutional review boards (IRBs) 12, 218
Intergovernmental Gene Technology Agreement (Australia) 183
International Air Transport Association (IATA) 60
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 4
CMC requirements 55
  common technical document (CTD) structure 106
definition of comparability 75
guidance documents 135
ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data 153
ICH M3(R2) guidance 151
International Organization for Standardization (ISO) 76, 77, 90
International Safe Transit Association 60
International Society for Computed Tomography (ISCT) 76, 77
International Society for Stem Cell Research (ISSCR) 144
investigational biologic drug products 137
investigational medicinal products (IMPs) 88
investigational new drugs (INDs) 71
animal models 40
CMC requirements 54
  preclinical assessment 51
storage and distribution 87
investigations 156
in vivo gene therapy 218
isolators 77
Japan

- adverse event reporting 155
- application and review process 155, 156
- clinical trial notification 154
- clinical trial operations 155
- clinical trials 153
- clinical trials conducted on ethical grounds 153
- CMC requirements 55
- conditional expedited approval system 147, 148
- first-in-human (FIH) studies 154
- good laboratory practice (GLP) 150
- good manufacturing practices 149
- guidance documents 157, 159
- guidelines for clinical research 143
- guidelines related to cell therapy 143
- history of regenerative medicine 5
- human stem cell guidelines 143
- legislations 143, 144
- market approval 155
- mutual recognition agreement (MRA) 150
- nonclinical safety studies 151
- patient registration database 159
- postmarketing surveillance (PMS) 156–158
- regulations 6, 19, 143–160
- Japan new drug applications (JNDAs) 155
- Joint Accreditation Committee ISCT-Europe and EBMT (JACIE) 59

JW Therapeutics 164, 174

K

- Kass, Leon 15
- Kymriah® (tisagenlecleucel) 17, 65, 72, 130, 135, 180, 182

L

- labeling
  - ATMPs 88
  - commercial manufacturing strategy 80
  - EU tissues and cells directives 88
  - GMO shipments 92
  - IMPs 88
  - of biologicals 181
  - of cryopreserved products 67
  - of tissue products 60
  - shipping labels 88, 92
  - laboratory controls 80
  - Lamberth, Royce 16
  - Laviv 72
  - lentivirus 26, 51
  - definition 218
  - product types 73
  - licensing
  - biologics license applications (BLAs) 51
  - CMC readiness 78
  - dealer’s license 200
  - dealings involving intentional release (DIR) licenses 185
  - dealings not involving intentional release (DNIR) licenses 185, 186
  - Innovative Licensing and Access Pathway (ILAP) 125, 217
  - licensed manufacturers 146
  - MAA license renewal 173
  - OGTR requirements 178
  - liquid nitrogen (LN2) 94
  - lisocabtagene maraleucel (Breyanzi®) 65
  - living drugs 71
  - logistics
    - of allogeneic therapies 86, 91, 93
    - of autologous therapies 86, 90, 91, 92
    - frozen and fresh conditions and 91
    - of gene therapies 86, 92–94
    - product-specific challenges 73
    - regulatory framework 86–89
  - logistics lanes 85, 87, 96
  - long-term follow up (LTFU) 26, 45, 46, 53
  - long-term follow up (LTFU) studies 112–113, 169
  - long-term safety 112–113
  - Lot Release Program 138
  - Luxturna (voretigene neparvovec-rzyl) 17, 51, 72, 130, 135, 186

M

- MACI 72
- MacLeod, Colin 3
- Malarkey, Mary Anne 103
- manufacturing 1, 24
  - automated systems 76, 77
  - commercial-scale 79–80
  - continuous 76
  - early stage considerations 40
example platforms 77
non-standardized platforms 25
optimization 75
points to consider 79–80
product-specific challenges 73
starting materials 25
strategies for commercial phase entry 77
manufacturing controls. See also chemistry,
manufacturing, and controls (CMC)
appropriate 75
establishment 71–80
recommended reading 83
sequential elements of establishing 75, 76
suggested points to consider 82
manufacturing facilities
accreditation 146
CGMP strategies 78
commercial manufacturing strategy 80
considerations for 81
design points 77, 81
inspections 81
on-site evaluation (OSE) 138
manufacturing license 146
manufacturing site concept
for allogeneic therapies 93
for autologous therapies 91, 92
market access 174
marketing authorization application (MAA)
accelerated approval procedures 172
breakthrough therapy drug procedures 172
case studies 174
conditional approval procedures 172
EU process and timeline 119, 120
Japan new drug application (JNDA) 155
license renewal 173
new drug submission (NDS) 138
postapproval variations 196
postmarketing vigilance requirements 197
priority review and approval procedures 172
procedures in China 171, 172
procedures in Singapore 192, 193–196, 197
requirements and process 193–196
Marks, Peter W. 103
master cell banks (MCBs) 59
definition 218
product-specific challenges 73
materials
commercial manufacturing strategy 80
product-specific challenges 73
McCarty, Maclyn 3
McNeill, Lorrie H. 103
medical devices 36
Medical Devices Regulations (MDR) 129, 131,
134
Medical Products Administrations (MPAs) 165
Medical Services Advisory Committee (MSAC)
186
medicinal products. See advanced therapy
medicinal products (ATMPs)
medicines. See also prescription medicines;
prescription medicines
definition of 181
Medicines Act (NZ) 187
Medicines and Healthcare products Regulatory
Agency (MHRA) 125
Medsafe 187
memoranda of understanding (MOUs) 150
Michigan 16
microbial vectors 55
Miescher. Friedrich 3
minimal manipulation 100, 131, 218
Missouri 16
mode of action (MOA)
biological product 30
definition of 30, 218
drug 31
primary. See primary mode of action (PMOA)
multi-luminance mobility test (MLMT) 43, 44
mutual acceptance of data (MAD) 151
mutual recognition agreements (MRAs) 150,
218
mycoplasma tests 66

N
National Academies of Sciences, Engineering,
and Medicine (US) 8
National Academy of Sciences (US) 13
National Bioethics Advisory Committee
(NBAC) 6
National Commission for the Protection of
Human Subjects of Biomedical and
Behavioral Research (US) 14
National Competent Authority (NCA) 6
National Conference of State Legislatures (US)
6
National Essential Drug List (NEDL) 174
National Health Act (Australia) 186
National Healthcare Security Administration (NHSA) 164, 174
National Health Commission (NHC) 163, 164
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) 76
National Institute of Standards (NIST) 76, 77
National Institutes for Food and Drug Control (NIFDC) 164
National Institutes of Health (NIH) 76
fetal tissue research policy 17
guidelines 13
Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) 9, 13, 14, 17
Human Embryo Research Panel 14
Human Fetal Tissue Research Ethics Advisory Board 17
Human Fetal Tissue Transplantation Ethics Advisory Panel 14
Office of Recombinant DNA Activities (ORDA) 12
Recombinant DNA Molecule Program Advisory Committee (RAC) 9, 12, 14
research funding 49, 50
National Medical Products Administration (NMPA) 163, 164, 171
National Reimbursement Drug List (NRDL), 174
National Research Act (US) 14
new drug submission (NDS) 138
New England Journal of Medicine 17
new organisms 188
New Substances Notification (NSN) Regulations (Organisms) 134
New Zealand (NZ) 187, 188
Current Guidelines on the Regulation of Therapeutic Products in New Zealand 187
Environmental Protection Authority (EPA) 188
Gene Technology Advisory Committee (GTAC) 187
legislation 187
next generation sequencing (NGS) 82
NIH Revitalization Act (US) 14
nonclinical studies
good laboratory practice (GLP) 150
Japanese Ministerial Ordinance 151
non-GLP proof-of-concept studies 52
Non-Satisfactory Notice (NSN) 137
non-viral vectors 50
No Objection Letter (NOL) 137
no observed adverse effect levels (NOAELs) 52
Norway 124
notice of compliance with conditions (NOC/c) 138
Novartis 17, 135
Novartis Gene Therapies 130
Novartis Pharmaceuticals 130, 180
Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) 13, 17
NR082 ophthalmic injection 164
nusinersen (Spinraza) 130
Obama, Barack 8, 16, 17
Office for Human Research Protections 12
Office of Blood Research and Review (OBRR) 18
Office of Cellular, Tissue, and Gene Therapies (OCTGT) 18
Office of Combination Products (OCP) 14, 32
Office of Policy and International Collaboration (OPIC) 131
Office of Recombinant DNA Activities (ORDA) 12
Office of the Gene Technology Regulator (OGTR) 177
cell and gene therapy product licenses 186
dealings involving intentional release (DIR) licenses 185
dealings not involving intentional release (DNIR) licenses 185, 186
license requirements 178
Office of Tissues and Advanced Therapies (OTAT) 6, 16, 18, 49
Division of Cellular and Gene Therapies (DCGT) 102, 105
organizational structure 104
Office of Vaccines Research and Review (OVRR) 18
off-target effects 26
off-the-shelf products 72
challenges 73
suggested points to consider  82
Oh, Steven  105
onasemnogene abeparvovec-xioi (Zolgensma)  130, 186
Oncorine  163, 174
on-site evaluation (OSE)  138
on-target off-tumor toxicity  26
optimization  40, 75
Organization for Economic Cooperation and Development (OECD)  151
orphan drug programs  139
Ortho-ACI chondrocytes  180, 182
Orthocell Ltd.  180
Osiris Therapeutics  130

P

packaging  80
patient preferences  43–44
patient registration system  159
peptide vaccines  73
peripheral blood mononuclear cells (PBMCs)  59
Pharmaceutical Affairs Act (PAA)  155
Pharmaceutical Affairs Law (PAL)  5, 144, 147
Pharmaceutical and Medical Devices Agency (PMDA)  5, 6
consultation process  143
consultations and meetings  152
Pharmaceutical and Medical Devices (PMD) Act (Japan)  144, 147, 153, 156, 159
Pharmaceutical Benefits Advisory Committee (PBAC)  186
Pharmaceutical Management Agency of NZ (PHARMAC)  187
Pharmaceutical Regulatory Information System (PRISM)  199
Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act)  5, 6
Phase 1 trials  49
Phase 2 trials  49
Phase 3 trials  49
phased trials  154
Phase III or licensing trials  78
pilot studies  52
plasmids  218
plasmid vectors  73
pluripotent stem cells (PSCs). See induced pluripotent stem cells (iPSCs)
polymerase chain reaction (PCR)  218
postapproval change management  173
postmarketing surveillance (PMS)  156–158
potency  25
potency testing  25
FDA guidance  55
US regulation  108
pre-BLA meetings  105
precision  204
preclinical assessment
  current trends  51
  key suggestions or recommendations  52
  US regulations  109
pre-IND meetings  104
pre-request for designation (pre-RFD)  32
Prescription Drug User Fee Act VII (PDUFA VII)  17
prescription medicines
  Australian Register of Therapeutic Goods (ARTG)  186
  facilitated review pathways  182, 184
  regulation in Australia  181–185
  standard review pathway  182
  TGA review pathways  178, 179
  prescription only medicines  181
President’s Council on Bioethics
  “Cloning Human Beings”  8
  formation  7, 15
primary mode of action (PMOA)  30
  definition  218
  determination by OCP  34
  regulatory definition  32
PRIME (PRIority MEdicines)  55, 218
priority review  139
priority review and approval procedures  172
Prochymal (Human Adult Stem Cells)  130
product consultation  192
production  80
Project Orbis  125, 185, 219
proof-of-concept studies  52
protocols  219
Provenge  72
Public Health Service (PHS) Act (US)  6
  Section 351  99
  Section 361  4, 15, 16, 99
public scrutiny  11
Purohit-Sheth, Tejashri  104
Q

QbD approach 82
quality by design (QbD) 219
quality control
commercial manufacturing strategy 80
regulations in China 166
quality target product profile (QTTP) 40, 219

R

Rabb, Harriet 6, 15
rapid microbial methods 66
rare diseases, gene therapy for 54, 111
rDNA technology 10
readiness, CMC 72, 78
reagents 107
RECELL 72
Recombinant DNA Molecule Program Advisory Committee (RAC)
creation 9
enhanced gene therapy review 11
Human Gene Therapy Subcommittee (HGTS) 10, 11, 12
mandate 9
reduction and dissolution 12
second generation 10
third generation 10
timeline 14
recombinant DNA (rDNA) 9
regenerative medical products
definition of 5, 147
Japanese application and review process 155, 156
Regenerative Medicine Advanced Therapy (RMAT) designation 55, 100–101
definition 219
development timeline 17
devices used with RMAT products 102
RMAT meetings 105
Regenerative Medicine Promotion Act (Japan) 144
regenerative medicines (RM)
Class I 146
Class II 146
Class III 146
combination products 29–36
definition of 4, 71, 219
distribution of medicines 85–96
EU regulation 117–126

future directions 203–207
history of 3–21
logistics lanes 85, 87, 96
manufacturing of 1
regulation in Singapore 191
regulatory frameworks 6
risk-based classification of 145, 146
standards development 76
types of products 1
unique properties of 23–26
US regulation 99–115
registration
Australian Register of Therapeutic Goods (ARTG) 178, 180, 182, 186
Drug Registration Regulation (DRR) 171
fees and timelines 196
Final Rule for Clinical Trials Registration and Results Information Submission (HHS) 12
Human Cell and Tissue Establishment Registration (FDA) 59
Institutional Biosafety Committee Registration Management System (IBC-RMS) 13
patient registration databases 159
registered products 164
registered protocols 12
retention of 196
safety registration databases 13
regulation manufacturing. See chemistry, manufacturing, and controls (CMC); See manufacturing controls
Regulation (EC) No 726/2004 4, 6, 119
Regulation (EC) No 1394/2007 4, 6, 117
regulatory frameworks
Canadian 129–130
current trends 51–54
EU 117–126
evolution of 206
future directions 206
Japan 143–160
logistics 86–89
US 14–17, 99–115
US, EU, and Japan 6, 19
regulatory professionals 205
regulatory review
expedited pathways 45
hurdles during 43–44
regulatory science (RS) strategy consultations 152
release testing
  considerations for 65
  samples for 66
Relma-cel 174
replication competent retrovirus (RCR) 112
requests for designations (RFDs)
  for combination products 32–33
  required information 34
Research Portfolio Online Reporting Tools (RePORT) 219
RESTOBA 180
retinal disorders, gene therapy for 54
retroviral vector-based human gene therapy products 55
Ricles, Laura 105
risk assessment 93, 114
risk assessment and risk management plans (RARMPs) 185
RNA editing 24
Rosenberg, Steven 11

S
safety, long-term 112–113
Safety of Human Cells, Tissues, and Organs for Transplantation Regulations (CTO Regulations) 129, 130, 131, 132, 135
safety reporting 199
scaffolds 219
Schultz, Kimberly 105
serious adverse events (SAEs)
  definition 219
  reporting 197, 198
  unexpected serious adverse drug reactions (USADRs) 199
severe combined immune deficiency (SCID) 11
Shanghai Sunway Biotech Co., Ltd 163
Shanghai Xinzhi 164
shelf-life
  of allogeneic therapies 92, 93
  of autologous therapies 91, 92
  of fresh finished products 91
Sherley v. Sebelius 16
shipping and handling
  product-specific challenges 73
  transport of starting cells or tissue 60–61
shipping labels
  EU tissues and cells directives 88
  example 88
  GMO shipments 92
SiBiono GeneTech Co. Ltd. 163
Singapore
  chemistry, manufacturing, and controls 197
  clinical trial applications 198, 200, 201
  CTGTP registration 196
  dealer’s license 200
  good manufacturing practice (GMP) 198
  Health Products (cell, tissue, and gene therapy products) Regulations 2021 191
  Health Products (Clinical Trials) Regulations 198
  Health Sciences Authority (HSA) 191, 192, 193, 196, 199
  marketing authorization application requirements and process 193–196, 197
  marketing authorization pathways 192
  postmarketing vigilance requirements 197
  registration fees and timelines 196
  regulatory environment 191–200
  requirements for safety reporting 199
  special access routes (SARs) 201
Single European Code (SEC) 58, 60, 61
Sista, Ramani 104
somatic cell therapy 10
  definition of 23
  US regulation of 107
somatic cell therapy medicinal products (SCTPs)
  classification of 4, 122
  definition 219
  legal definition 121
Spark Therapeutics 17, 130, 135
Special Access Program (SAP) 139, 219
special access routes (SARs) 201
Spink, Katy 205, 207
Spinraza (nusinersen) 130
spray on cells 72
Standard Coordinating Body (SCB) 77
standards development 76
starting materials
  EU requirements 123
  human cell or tissue-based 57–62
  manufacturing factors 25
  special considerations 57–62
  traceability 124
  transport 60–61
Stem Cell Research Enhancement Act (US) 15
stem cells
definition 220
embryonic. See embryonic stem cells (ESCs)
engineered 216
first human trials 16
induced. See induced pluripotent stem cells
(iPSCs)
therapeutic product types 73
sterility testing
culture-based 66
samples for 67
storage
of advanced therapy investigational medicinal
products 86
cryopreservation 64
EU GMP guidance for advanced therapy
medicinal products 88
EU tissues and cells directives 87
of frozen regenerative medicines 94
storage facilities
for allogeneic therapies 92, 94
need for 92, 94
supply chains
of allogeneic therapies 93
of autologous therapies 90
of gene therapies 95
Sweden 150
Switzerland 150

T
talimogene laherparepvec (Imlygic) 183
target product profile (TPP) 40
T-Cells 180
Tecartus® (brexucabtagene autoleucel) 65, 130, 182
technical documents. See common technical
document (CTD)
temperature conditions
for allogeneic therapies 92, 93
for autologous therapies 91, 92
terminology 4, 164
TheraCys 72
therapeutic dose selection 41
Therapeutic Goods Act (Australia) 177, 181
Therapeutic Goods Administration (TGA) 177,
178, 179
Thomson, James 6, 15
tisagenlecleucel (Kymriah®) 65, 130, 180, 182
tissue-engineered products (TEPs)
classification of 4, 122
definition 220
legal definition 121
tissue establishments 58–59
tissue labeling 60
tissue products
labeling requirements 60
regulatory environment in Singapore 191–200
Tissue Reference Group (TRG) 14, 102, 220
tissue rules (FDA) 11
tissue therapy regulations 10
toxicity, on-target off-tumor 26
traceability 89
considerations for 58
definition of 220
EU requirements 87, 124
equivalence tracking portal status information 89
tracking devices 89
transforming principle 3
transport
from procurement site to manufacturing site
60–61
shipping labels 88
of starting cells or tissue 60–61
21st Century Cures Act (US) 4, 6, 17, 99,
100–101
Type 1 use 149, 153
Type 2 use 149
Type A meetings 103
Type B meetings 102, 103
Type C meetings 103

U
unexpected serious adverse drug reactions
(USADRs) 199
United Kingdom (UK)
clinical trials regulation 126
medicines regulation 117, 125
United States (US)
Clinton Administration 6, 15
current state laws for embryonic stem cell and
cloning research 7
development timeline of guidances, regulations,
and laws 14–17
Guideline for Human Embryonic Stem Cell
Research 8
Index

Obama Administration 16
President’s Council on Bioethics 7, 15
regulation of combination products 29
regulation of regenerative medicine 4, 6, 14–17, 19, 99–115
Untitled Letters (FDA) 102
US Department of Defense (DOD) 76
US Department of Health and Human Services (HHS)
  Final Rule for Clinical Trials Registration and Results Information Submission 12
policies 17
US Food and Drug Administration (FDA) 6, 12, 13
Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products 10
Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 106
Center for Biologics Evaluation and Research (CBER) 18, 49
clinical trials for human stem cell therapy 16
definition of combination products 29
definition of gene therapy 23
developmental timeline 13, 14, 15, 16, 17
draft guidance documents 77
enforcement actions 102
expedited review pathways 45
first FDA-approved AAV gene therapy 43
good tissue practices (GTPs) 57
Guidance for Industry Points to Consider in Human Somatic Cell Therapy and Gene Therapy 10
Human Cell and Tissue Establishment Registration website 59
meeting formats 106
meeting preparation 106
meetings 102–103
Office of Combination Products (OCP) 32
Project Orbis 125, 219
regulatory framework 99
requirements for CMC 54
requirements for comparability studies 75
suggested guidance documents 82
Tissue Reference Group (TRG) 102
tissue rules 11
Untitled Letters 102
Warning Letters 16
US Pharmacopeia (USP) 76, 136

V
Varmus, Harold 12, 13
vectors
definition 220
design for gene therapy 40
testing 112
Verdun, Nicole 103
verification 149
viral testing 108
viral vectors 50
voretigene neparvovec-rzyl (Luxturna) 130, 186

W
Weinberger, Caspar W. 9
Wei, Zexi 163
Wilmot, Ian 5
Wolff, CF 3
working cell banks (WCBs) 59, 220
World Health Organization 19

X
xenotransplant products 73

Y
Yescarta® (axicabtagene ciloleucel) 17, 65, 72, 130, 135, 138, 174, 182

Z
Zimmerman review 187
Zolgensma (onasemnogene abeparvovec-xioi) 17, 130, 135, 186